A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

OBJECTIVE: To determine the current disease-modifying anti-rheumatic drug (DMARD) preferences of UK consultant rheumatologists. METHODS: A questionnaire was sent in May 2002. We asked which DMARD(s) was most frequently preferred first and sought the most typical sequence of DMARDs, including DMARD c...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Jobanputra, P, Wilson, J, Douglas, K, Burls, A
Formato:	Journal article
Idioma:	English
Publicado em:	2004

Registos relacionados

A SURVEY OF DMARD PREFERENCES OF UK RHEUMATOLOGISTS
Por: Douglas, K, et al.
Publicado em: (2003)

Doctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
Por: T. Martijn Kuijper, et al.
Publicado em: (2017-04-01)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
Por: Mysler E, et al.
Publicado em: (2021-06-01)

When the first visit to the rheumatologist is established rheumatoid arthritis
Por: Taylor, P, et al.
Publicado em: (2020)

Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone
Por: Edwards, C, et al.
Publicado em: (2008)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
Por: Michael D George, et al.
Publicado em: (2021-04-01)

Periodontal Health as Perceived by Rheumatologists and Rheumatoid Arthritis Patients
Por: Natasha Proud, et al.
Publicado em: (2023-04-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
Por: Maria Sergeevna Voronina, et al.
Publicado em: (2012-10-01)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
Por: Kai Wei, et al.
Publicado em: (2022-03-01)

Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
Por: Basant Kumar Maheshwari
Publicado em: (2018-01-01)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation
Por: Jobanputra, P, et al.
Publicado em: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
Por: Jobanputra, P, et al.
Publicado em: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation
Por: P. Jobanputra, et al.
Publicado em: (2002-01-01)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
Por: Juthamas Prawjaeng, et al.
Publicado em: (2023-05-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
Por: Barton, P, et al.
Publicado em: (2004)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
Por: Barton, P, et al.
Publicado em: (2004)

A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference
Por: Hamre HJ, et al.
Publicado em: (2018-03-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis
Por: P Barton, et al.
Publicado em: (2004-03-01)

Elderly-onset rheumatoid arthritis: an outlook from a practicing rheumatologist
Por: Ch. Baimukhamedov
Publicado em: (2020-09-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis - Introduction
Por: Barton, P, et al.
Publicado em: (2004)

Patients’ and rheumatologists’ perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis
Por: Laurette van Boheemen, et al.
Publicado em: (2020-09-01)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
Por: Clark, W, et al.
Publicado em: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Por: Clark, W, et al.
Publicado em: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Por: Clark, W, et al.
Publicado em: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
Por: W Clark, et al.
Publicado em: (2004-09-01)

Individual DMARDs have different effects on the likelihood of developing septic arthritis in adults with rheumatoid arthritis
Por: Edwards, C, et al.
Publicado em: (2005)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
Por: James Cheng-Chung Wei, et al.
Publicado em: (2023-07-01)

Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion
Por: Emiliano Marasco, et al.
Publicado em: (2023-09-01)

Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
Por: Basiru Ahmad Zago, et al.
Publicado em: (2020-12-01)

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
Por: Tillett, W, et al.
Publicado em: (2020)

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients
Por: Hazan Karadeniz, et al.
Publicado em: (2022-04-01)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
Por: Soo-Kyung Cho, et al.
Publicado em: (2017-12-01)

Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
Por: Esteban A. Gomez, et al.
Publicado em: (2020-10-01)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
Por: Seogsong Jeong, et al.
Publicado em: (2022-07-01)

Challenges in implementing treat-to-target in rheumatoid arthritis: a perspective from Brazilian rheumatologists
Por: Adriana Maria Kakehasi, et al.
Publicado em: (2024-08-01)

Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making
Por: Bolge SC, et al.
Publicado em: (2016-06-01)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Por: Ruiz Garcia, V, et al.
Publicado em: (2014)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Por: Ruiz Garcia, V, et al.
Publicado em: (2011)

To flare or not to flare: patients’ and rheumatologists’ perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis
Por: Delphine Bertrand, et al.
Publicado em: (2024-02-01)

The use of methotrexate in rheumatoid arthritis. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”
Por: E. L. Nasonov, et al.
Publicado em: (2023-08-01)